Through the deal, Vivakor plans to support VivaCeuticals' international expansion, new product introduction, and also focus on the commercialization of products.
Vivakor CEO and chairman Matt Nicosia said that sales through Regeneca Worldwide continue to rise.
As a result, the company expects VivaCeutical's revenue contribution to be at least $100m over the next five years through the introduction of new products, international expansion, and brand awareness, Nicosia added.
